Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: The UK Perspective

Author： Karnon Jonathan

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.3, 2006-01, pp. : 237-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK

By Nuijten M.

PharmacoEconomics, Vol. 16, Iss. 4, 1999-10 ,pp. : 379-397

Adis International

Access to resources Recommend Favorite

Low rate of cardiovascular AEs with adjuvant letrozole, tamoxifen

Reactions Weekly, Vol. 1, Iss. 1182, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 23, Iss. 5, 2007-05 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of interferon-α₂ as adjuvant therapy in malignant melanoma

By Lafuma Antoine Grob Jean Jacques

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 3, 2003-03 ,pp. : 343-349

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide

By Liubao Peng

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 873-886

Adis International

Access to resources Recommend Favorite